Latest News

Sienna and VivaZome to Evaluate EXO-NETᵀᴹ for VivaZome’s Exosome-based Therapeutics
08-Nov-2019

VivaZome is developing exosome-based therapies for debilitating and/or life-threatening diseases .. READ MORE

Sienna and Minomic Enter Collboration Agreement to Develop Pancreatic Cancer Test
31-Oct-2019

Pancreatic cancer is the most lethal cancer in humans, with a 5-year survival rate of less than 10.. READ MORE

CEO Appointment
16-Oct-2019

Carl Stubbings will take up the role of CEO with immediate effect. Carl has been a non executive.. READ MORE

Investor Information

Sienna is a public listed company headquartered in Melbourne, Australia. In August 2017, Sienna listed on the Australian Securities Exchange under the ticker symbol SDX. The company is governed by an experienced board and management team. Sienna has benefited from over $7.4M in R&D Tax Incentive refunds and government grant programs, significantly bolstering investor contributions and facilitating the progress and growth to date. READ MORE

 

Research

Sienna’s core activities have historically focused on the clinical translation of biomarkers using novel diagnostic technologies for applications in pathology laboratories. The development of inexpensive, high performing in vitro diagnostic tests is expected to lead to radical changes in the approach to care and assessment of cancer patients – a change welcomed by clinicians and governments.  READ MORE

 

About Sienna

Sienna is a medical technology company focussed on the development and commercialisation of novel IVD (in vitro diagnostic) tests. Sienna manufactures IVD products for pathology laboratories to use in their menu of testing services. READ MORE

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059